Myopic Choroidal Neovascularization with Neovascular Signal Around Perforating Scleral Vessel Prone to Recur After Anti-VEGF Therapy

Overview

Journal Eye Vis (Lond)

Publisher Biomed Central

Specialty Ophthalmology

Date 2024 Feb 6

PMID 38321461

Authors

Xiangjun She

Wangjing Yao

Gongyu Huang

Zhi Liang

Jin Xie

Jiwei Tao

Sulan Wu

Jianbo Mao

Yiqi Chen

Yun Zhang

Lijun Shen

Affiliations

Soon will be listed here.

Abstract

Background: To compare the recurrence of myopic choroidal neovascularization (mCNV) based on the neovascular signal of mCNV around the perforating scleral vessel (PSV).

Methods: A consecutive series of naïve patients with mCNV accepted anti-VEGF therapy with a minimum 12-month follow-up period. The neovascular signal relationship between PSV and mCNV were classified into the presence of neovascular signal of CNV around PSV or not. The recurrence of mCNV, best-corrected visual acuity (BCVA), hyperreflective foci height, CNV area and CNV flow area were analyzed between two groups.

Results: Neovascular signal of CNV around PSV was detected in 20 eyes (39.2%). The one-year recurrence rate in the group with neovascular signal of CNV around PSV was significantly higher than that in the group without neovascular signal of CNV around PSV (P = 0.045). The recurrence time in the group with neovascular signal around PSV was shorter than that in the group without neovascular signal around PSV (P = 0.030). Cox proportional hazard model showed that the presence of neovascular signal of CNV around PSV [hazard ratio (HR): 2.904] and subfoveal choroidal thickness ≤ 50 μm (HR: 0.368) were risk factors for recurrence of mCNV. In the group with neovascular signal around PSV, the BCVA was worse (P = 0.024) and the CNV flow area was more unstable (P = 0.027) after therapy.

Conclusions: PSV was commonly detected in patients with mCNV. The presence of neovascular signal of CNV around PSV was prone to recur with a shorter time in mCNV patients.

References

Yang H, Kim J, Kim J, Joe S . Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Am J Ophthalmol. 2013; 156(6):1201-1210.e2. DOI: 10.1016/j.ajo.2013.08.002. View

Querques G, Corvi F, Balaratnasingam C, Casalino G, Battaglia Parodi M, Introini U . Lacquer Cracks and Perforating Scleral Vessels in Pathologic Myopia: A Possible Causal Relationship. Am J Ophthalmol. 2015; 160(4):759-66.e2. DOI: 10.1016/j.ajo.2015.07.017. View

Wong C, Phua V, Lee S, Wong T, Cheung C . Is Choroidal or Scleral Thickness Related to Myopic Macular Degeneration?. Invest Ophthalmol Vis Sci. 2017; 58(2):907-913. DOI: 10.1167/iovs.16-20742. View

Asakuma T, Yasuda M, Ninomiya T, Noda Y, Arakawa S, Hashimoto S . Prevalence and risk factors for myopic retinopathy in a Japanese population: the Hisayama Study. Ophthalmology. 2012; 119(9):1760-5. DOI: 10.1016/j.ophtha.2012.02.034. View

Cheung C, Arnold J, Holz F, Park K, Lai T, Larsen M . Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management. Ophthalmology. 2017; 124(11):1690-1711. DOI: 10.1016/j.ophtha.2017.04.028. View

Giuffre C, Querques L, Carnevali A, De Vitis L, Bandello F, Querques G . Choroidal neovascularization and coincident perforating scleral vessels in pathologic myopia. Eur J Ophthalmol. 2017; 27(2):e39-e45. DOI: 10.5301/ejo.5000875. View

Kang H, Koh H . Ocular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study. Retina. 2013; 33(8):1613-22. DOI: 10.1097/IAE.0b013e318285cc24. View

Ohno-Matsui K, Ikuno Y, Lai T, Cheung C . Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res. 2017; 63:92-106. DOI: 10.1016/j.preteyeres.2017.10.005. View

Jain M, Narayanan R, Jana P, Mohamed A, Raman R, Verkicharla P . Incidence, predictors and re-treatment outcomes of recurrent myopic choroidal neo-vascularization. PLoS One. 2022; 17(7):e0271342. PMC: 9302801. DOI: 10.1371/journal.pone.0271342. View

10.

Ikuno Y, Ohno-Matsui K, Wong T, Korobelnik J, Vitti R, Li T . Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study. Ophthalmology. 2015; 122(6):1220-7. DOI: 10.1016/j.ophtha.2015.01.025. View

11.

Park U, Lee E, Yoon C, Oh B . Progression pattern of myopic maculopathy according to the severity of diffuse chorioretinal atrophy and choroidal thickness. Sci Rep. 2022; 12(1):3099. PMC: 8866404. DOI: 10.1038/s41598-022-07172-w. View

12.

Hsu C, Lai T, Hsieh Y, Ho T, Yang C, Yang C . Baseline predictors for good visual gains after anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization. Sci Rep. 2022; 12(1):6800. PMC: 9042908. DOI: 10.1038/s41598-022-10961-y. View

13.

Ashraf M, Sampani K, Abu-Qamar O, Cavallerano J, Silva P, Aiello L . Optical Coherence Tomography Angiography Projection Artifact Removal: Impact on Capillary Density and Interaction with Diabetic Retinopathy Severity. Transl Vis Sci Technol. 2020; 9(7):10. PMC: 7414622. DOI: 10.1167/tvst.9.7.10. View

14.

Takao-Okuma H, Terao R, Nagahara M, Azuma K, Inoue T, Uemura Y . Distribution of recurrence time intervals after anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization. Can J Ophthalmol. 2020; 56(2):137-138. DOI: 10.1016/j.jcjo.2020.08.004. View

15.

Ishida T, Watanabe T, Yokoi T, Shinohara K, Ohno-Matsui K . Possible connection of short posterior ciliary arteries to . Br J Ophthalmol. 2018; 103(4):457-462. DOI: 10.1136/bjophthalmol-2018-312015. View

16.

Wakabayashi T, Ikuno Y, Oshima Y, Hamasaki T, Nishida K . Aqueous Concentrations of Vascular Endothelial Growth Factor in Eyes with High Myopia with and without Choroidal Neovascularization. J Ophthalmol. 2013; 2013:257381. PMC: 3606763. DOI: 10.1155/2013/257381. View

17.

Yao W, Xu J, She X, Yu J, Liang Z, Ye X . Perforating scleral vessels adjacent to myopic choroidal neovascularization achieved a poor outcome after intravitreal anti-VEGF therapy. Front Med (Lausanne). 2022; 9:1065397. PMC: 9792597. DOI: 10.3389/fmed.2022.1065397. View

18.

Ruiz-Medrano J, Almazan-Alonso E, Puertas M, Flores-Moreno I, Garcia-Zamora M, Kudsieh B . ASSESSMENT AND ROLE OF ARTERY-VEIN COMPLEX IN MYOPIC CHOROIDAL NEOVASCULARIZATION USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina. 2023; 43(9):1544-1549. PMC: 10442109. DOI: 10.1097/IAE.0000000000003852. View

19.

Muakkassa N, Chin A, De Carlo T, Klein K, Baumal C, Witkin A . CHARACTERIZING THE EFFECT OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY ON TREATMENT-NAIVE CHOROIDAL NEOVASCULARIZATION USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. Retina. 2015; 35(11):2252-9. DOI: 10.1097/IAE.0000000000000836. View

20.

Xie J, Chen Q, Yu J, Zhou H, He J, Wang W . Morphologic Features of Myopic Choroidal Neovascularization in Pathologic Myopia on Swept-Source Optical Coherence Tomography. Front Med (Lausanne). 2021; 7:615902. PMC: 7785753. DOI: 10.3389/fmed.2020.615902. View